Skip to Content

'
Edward TH Yeh, M.D.

Present Title & Affiliation

Primary Appointment

Professor and Chairman, Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
A Conversation with a Living Legend Professor, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Edward T.H. Yeh received his bachelor's degree in biochemistry from the University of California, Berkeley, and his medical degree from the University of California, Davis.   Following medical residency, he completed a post-doctoral fellowship in Immunology at Harvard Medical School.  In 1987, he was appointed Assistant Professor of Medicine at the Massachusetts General Hospital, Harvard Medical School.  In 1992, Dr. Yeh joined the faculty of The University of Texas Health Science Center at Houston. In 2000, he became the founding chair of the Department of Cardiology at The University of Texas MD Anderson Cancer Center. 

Dr. Yeh established a new field called Onco-cardiology that specializes in providing personalized, comprehensive cardiac care to cancer patients. He discovered that Topoisomerase-IIβ (Top2b) mediates anthracycline-induced cardiotoxicity. This finding heralds in a new age of personalized cardio-protection for patient undergoing chemotherapy.  He has made fundamental contributions in biochemistry, biology and medicine through the discovery of two ubiquitin-like proteins that exemplify the importance of post-translational protein modification. In 1996, he discovered Sentrin, which later was named SUMO (Small Ubiquitin-like Modifier). He showed that SUMO modification can be reversed by a family of Sentrin/SUMO-specific proteases (SENPs). This biochemical pathway is important in the regulation of gene transcription, DNA replication/repair, signal transduction, and cellular metabolism. In 1997, he discovered another ubiquitin-like protein, NEDD8, and showed the importance of NEDD8 in breast cancer development. Earlier in his career, he elucidated the biosynthetic intermediates of the glycosyl-phosphtidylinositol (GPI) anchor and participated in the discovery of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria. He also made major contributions in the use of adult stem cells to treat patients who suffer from heart attack and heart failure.  Dr. Yeh received grants from the National Institute of Health, Cancer Prevention Research Institute of Texas, and Department of Defense. He was a Massachusetts General Hospital/Upjohn Scholar, Arthritis Investigator of Arthritis Foundation, and Established Investigator of the American Heart Association. He has written over 200 scientific papers and book chapters, many of which are landmark contributions to science and medicine.

Among his many honors, Dr. Yeh was elected to memberships in Academia Sinica, the Association of American Physicians, and the American Society for Clinical Investigation.  He was selected as the Distinguished Alumnus of the University of California, Davis Medical School and has served for ten years as Associate Editor of Circulation.  Dr. Yeh is a current member of the Editorial Board of Circulation, Texas Heart Institute Journal, and Journal of Biological Chemistry. He has held prominent positions as the President of the Houston Cardiology Society, President of the board of American Heart Association, Houston Chapter, and board member of the American Heart Association, Texas and South Central Affiliate.  He was the medical honoree of the American Heart Association, Houston Heart Ball in 2011.  He is America’s Top Cardiologist and Best Doctors in America.

Research Interests

Molecular basis of anthracycline cardiotoxicity

Adult stem cells in the treatment of heart disease

Pathophysiology of SUMOylation and De-SUMOylation

Education & Training

Degree-Granting Education

1980 University of California, Davis, CA, MD, Medicine
1976 University of California, Berkeley, CA, BA, Biochemistry

Postgraduate Training

7/1992-6/1995 Clinical Fellow in Cardiology, Cardiology, The University of Texas - Houston Health Science Center, Houston, TX
7/1986-6/1987 Clinical Fellow in Rheumatology, Rheumatology, Massachusetts General Hospital, Boston, MA
7/1983-6/1986 Research Fellowship, Immunology, Harvard Medical School, Boston, MA

Board Certifications

1/1999 Nuclear Cardiology
1/1995 Cardiovascular Diseases
1993 Rheumatology
1/1983 Internal Medicine

Honors and Awards

2013 Mc Nair Scholar Award
2012 Lifetime Achievement Award, Society of Chinese Bioscientists in America, Texas Chapter
2011 Heart Ball Medical Honoree, American Heart Association-Houston
2007-present Best Doctors, Elected to Best Doctors in America
2007 America's Top Cardiologists
2006 Academician, Academia Sinica, Republic of China
2005 Outstanding Advocate Award, American Heart Association-Houston
2001 Distinguished Alumnus Award, U. C. Davis Medical School
2000 Association of American Physicians
1993 American Society of Clinical Investigation
1992-1999 Established Investigator, American Heart Association
1987-1990 Investigator Award, Arthritis Foundation
1987-1990 Upjohn/Massachusetts General Hospital Scholar Award
1973-1974 Kraft Prize for Undergraduates, U.C. Berkeley

Selected Publications

Peer-Reviewed Original Research Articles

1. Qi Y, Wang J, Bomben VC, Li DP, Chen SR, Sun H, Xi Y, Reed JG, Cheng J, Pan HL, Noebels JL, Yeh ET. Hyper-SUMOylation of the Kv7 Potassium Channel Diminishes the M-Current Leading to Seizures and Sudden Death. Neuron 83(5):1159-71, 9/2014. PMID: 25189211.
2. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the Molecular Basis of Doxorubicin-Induced Cardiotoxicity. Nat Med 18(11):1639-42, 11/2012. e-Pub 10/28/2012. PMID: 23104132.
3. Bawa-Khalfe T, Lu LS, Zuo Y, Huang C, Dere R, Lin FM, Yeh ET. Differential Expression of SUMO-Specific Protease 7 Variants Regulates Epithelial Mesenchymal Transition. Proc Natl Acad Sci U S A 109(43):17466, 10/23/2012. e-Pub 10/8/2012. PMCID: PMC3491469.
4. Van Nguyen T, Angkasekwinai P, Dou H, Lin FM, Lu LS, Cheng J, Chin YE, Dong C, Yeh ET. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell 45(2):210-221, 1/27/2012. PMCID: PMC3269036.
5. Wang J, Najjar A, Zhang S, Rabinovich B, Willerson JT, Gelovani JG, Yeh ET. Molecular Imaging of Mesenchymal Stem Cell: Mechanistic Insight into Cardiac Repair following Experimental Myocardial Infarction. Circ Cardiovasc Imaging 5(1):94-101, 1/2012. e-Pub 12/1/2011. PMCID: PMC3273544.
6. Dou H, Huang C, Singh M, Carpenter PB, Yeh ET. Regulation of DNA Repair through De-SUMOylation and SUMOylation of Replication Protein a Complex. Mol Cell 39(3):333-345, 8/13/2010. PMCID: PMC2928994.
7. Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem 285(33):25859-66, 8/13/2010. e-Pub 6/15/2010. PMCID: PMC2919148.
8. Wang J, Zhang S, Rabinovich B, Bidaut L, Soghomonyan S, Alauddin MM, Bankson JA, Shpall E, Willerson JT, Gelovani JG, Yeh ET. Human CD34+ Cells in Experimental Myocardial Infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res 106(12):1904-11, 6/2010. PMID: 20448213.
9. Kang X, Qi Y, Zuo Y, Wang Q, Zou Y, Schwartz RJ, Cheng J, Yeh ET. SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell 38(2):191-201, 4/2010. PMID: 20417598.
10. Cheng J, Kang X, Zhang S, Yeh ET. SUMO-specific protease 1 is essential for stablization of HIFΑ 1α during hypoxia. Cell 131(3):584-95, 11/2007. PMCID: PMC2128732.
11. Zhang S, Shpall E, Willerson JT, Yeh ETH. Fusion of Human Hematopoietic Progenitor Cells and Murine Cardiomyocytes Is Mediated by α4 β1/Vascular Cell Adhesion Molecule-1 Interaction. Circ Res 100/5:693-702, 3/2007. PMID: 17303762.
12. Gao F, Cheng J, Shi T, Yeh ET. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription. Nat Cell Biol 8(10):1171-7, 10/2006. e-Pub 9/2006. PMID: 16998474.
13. Yeh ETH, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108:2070-3, 10/2003. PMID: 14568894.
14. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-8, 10/2000. PMID: 11056086.
15. Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM, Yeh ETH. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157(10):4277-81, 11/1996. PMID: 8906799.
16. DeGasperi R, Thomas L, Sugiyama E, Chang HM, Beck PJ, Orlean P, Albright C, Waneck G, Sambrook J, Warren C, Yeh ETH. Correction of a defect in mammalian GPI anchor biosynthesis by a transfected yeast gene. Science 250(4983):988-991, 1990. PMID: 1978413.
17. Yeh ETH, Reiser H, Bamezai A, Rock KL. TAP transcription and phosphatidylinositol linkage mutants are defective in activation through the T cell receptor. Cell 52(5):665-74, 3/1988. PMID: 2894252.

Grant & Contract Support

Title: Eradication of Doxorubicin-induced Cardiotoxicity through Molecular Targeting
Funding Source: UTMDACC Knowledge Gap Award
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2014
 
Title: Identification of Topoisomerase-II beta as the primary target of doxorubicin-induced cardiotoxicity and defining the mechanisms of action
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2016
 
Title: De-SUMOylation and the Hypoxic Response
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 3/1/2009 - 12/31/2014

Last updated: 8/26/2014